Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY 4.0Frontiers in Immunology

ULBP2–NKG2D signaling in cancer immunity: immune surveillance, immune escape, and therapeutic targeting

5 affiliations
  1. 1Department of General Surgery, Lanzhou University Second Hospital
  2. 2The Second Clinical Medical School, Lanzhou University
  3. 3Gansu Provincial Industrial Technology Center for Cancer Immunotherapy, Lanzhou University Second Hospital
  4. 4Gansu Tumor Immunology Basic Disciplines Research Center, The Second Hospital & Clinical Medical School, Lanzhou University
  5. 5Gansu Province High-Altitude High-Incidence Cancer Biobank, Lanzhou University Second Hospital

Abstract

UL16-binding protein 2 (ULBP2) is a stress-inducible ligand of natural killer group 2 member D (NKG2D) that connects cellular stress to immune surveillance. Its consequences in cancer depend on membrane accessibility, ligand density, proteolytic shedding, soluble-ligand exposure, duration of stimulation, and effector-cell fitness rather than bulk expression alone. Accessible membrane ULBP2 can support NKG2D–DAP10-dependent natural killer (NK) cell cytotoxicity and CD8 ⁺ T-cell costimulation, whereas shedding reduces cell-surface ligand and can generate soluble ULBP2 (sULBP2). Chronic surface-ligand exposure has been associated with NKG2D adaptation in heterologous mouse models; direct human in-vivo validation and quantitative exposure thresholds remain unavailable. In clinical cohorts, associations between circulating sULBP2 and prognosis do not establish that sULBP2 itself mediates immunosuppression. This review distinguishes ULBP2-specific observations from pan-NKG2D-ligand findings and platform-based extrapolations. It critically evaluates molecular regulation, immune activation and escape, biomarker assays, and CAR-based therapies, multispecific engagers, antibodies, and antibody–drug conjugates (ADCs). EVOLVE104 recognizes ULBP2/5/6 and is under phase I investigation, but the available public sources contain no mature clinical efficacy or safety outcomes; ULBP2-specific CAR-T approaches remain preclinical and ULBP2-directed ADCs lack target-developability validation. Translation will require matched measurements of surface ULBP2 and sULBP2, human-relevant normal-tissue testing, functional immune readouts, and construct-specific assessment of target selectivity, internalization, and exposure.

Related

  1. The SCF/KIT signaling pathway in multisystem diseases: Mechanisms and therapeutic targeting
    Ruidie Ma, Xueliang Wang, Yingbing Mei
    Science ProgressPeer-reviewedCC BY-NC 4.0Full textImmunologyPMC
  2. TREX1 in cancer immunity: from molecular mechanism to pharmacological targeting
    Yuan-Yuan Wu, Wei-Lan Li, Hua Shao +1
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
  3. Targeting the IRE1α/XBP1 pathway in type 2 diabetes mellitus: from ER stress signaling to therapeutic opportunity.
    Olabisi Tajudeen Obafemi, Ademola Olabode Ayeleso, Bidemi Emmanuel Ekundayo +4
    Molecular biology reportsPeer-reviewedCC BYFull text1 citedCell biologyEurope PMC
  4. Dendritic cell diversity and dysfunction in cancer: implications for immunotherapy and therapeutic targeting
    Rong Wang, Yi Chen, Yan-fen Fang
    Acta Pharmacologica SinicaPeer-reviewedLicence not statedFull text2 citedImmunologyPMC
  5. Hypoxic Preconditioning Restores NK Cell Metabolic Fitness by Attenuating MAPK Signaling to Potentiate Antitumor Immunity in Lung Cancer
    Dian Zhuang, Xiaoyue Zhu, Na Wang +10
    Advanced SciencePeer-reviewedCC BY 4.0Full textImmunologyPMC
BibTeX
@article{han2026ulbp2nkg2d,
  title = {{ULBP2–NKG2D signaling in cancer immunity: immune surveillance, immune escape, and therapeutic targeting}},
  author = {Haobo Han and Weiwen Cai and Ruohan Ma and Biao Ding and Long Qin and Zuoyi Jiao},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = nov,
  doi = {10.3389/fimmu.2026.2012358},
  url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.2012358/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - ULBP2–NKG2D signaling in cancer immunity: immune surveillance, immune escape, and therapeutic targeting
AU  - Haobo Han
AU  - Weiwen Cai
AU  - Ruohan Ma
AU  - Biao Ding
AU  - Long Qin
AU  - Zuoyi Jiao
PY  - 2026
DA  - 2026/11/16
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.2012358
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2026.2012358/full
AB  - UL16-binding protein 2 (ULBP2) is a stress-inducible ligand of natural killer group 2 member D (NKG2D) that connects cellular stress to immune surveillance. Its consequences in cancer depend on membrane accessibility, ligand density, proteolytic shedding, soluble-ligand exposure, duration of stimulation, and effector-cell fitness rather than bulk expression alone. Accessible membrane ULBP2 can support NKG2D–DAP10-dependent natural killer (NK) cell cytotoxicity and CD8 ⁺ T-cell costimulation, whereas shedding reduces cell-surface ligand and can generate soluble ULBP2 (sULBP2). Chronic surface-ligand exposure has been associated with NKG2D adaptation in heterologous mouse models; direct human in-vivo validation and quantitative exposure thresholds remain unavailable. In clinical cohorts, associations between circulating sULBP2 and prognosis do not establish that sULBP2 itself mediates immunosuppression. This review distinguishes ULBP2-specific observations from pan-NKG2D-ligand findings and platform-based extrapolations. It critically evaluates molecular regulation, immune activation and escape, biomarker assays, and CAR-based therapies, multispecific engagers, antibodies, and antibody–drug conjugates (ADCs). EVOLVE104 recognizes ULBP2/5/6 and is under phase I investigation, but the available public sources contain no mature clinical efficacy or safety outcomes; ULBP2-specific CAR-T approaches remain preclinical and ULBP2-directed ADCs lack target-developability validation. Translation will require matched measurements of surface ULBP2 and sULBP2, human-relevant normal-tissue testing, functional immune readouts, and construct-specific assessment of target selectivity, internalization, and exposure.
SN  - 1664-3224
ER  -